Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

James Jenkins

Psychiatry N. Charleston, SC Medical Doctor

NPI 1861499816 CMS profile 265775

3300 West Montague Ave, Suite 203, N. Charleston, SC 29418

Open in the dashboard

General payments

$2,952

175 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, James Jenkins of N. Charleston, SC is reported in the CMS Open Payments database as having received $2,952 across 175 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $224 12
2021 General $1,032 60
2020 General $814 51
2019 General $884 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Jenkins
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to James Jenkins were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year James Jenkins Psychiatry median Middle half National median
2019 $884 $184 $59–$605 $163
2020 $814 $119 $36–$372 $114
2021 $1,032 $143 $43–$576 $132
2022 $224 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Otsuka America Pharmaceutical, Inc. $736 43 payments
  2. Sunovion Pharmaceuticals Inc. $375 20 payments
  3. ITI, Inc. $355 17 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $225 10 payments
  5. Lundbeck LLC $167 10 payments
  6. AbbVie, Inc. $133 15 payments
  7. Allergan Inc. $116 12 payments
  8. Supernus Pharmaceuticals, Inc. $115 4 payments
  9. Bausch Health US, LLC $112 7 payments
  10. Jazz Pharmaceuticals Inc. $86 5 payments
  11. Other $532 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,942 173 payments
  2. Education $11 2 payments
Products named General payments · program years 2019–2022
  1. REXULTI Psychiatry $627 36 payments
  2. LATUDA $375 20 payments
  3. CAPLYTA $355 17 payments
  4. TRINTELLIX $156 6 payments
  5. VRAYLAR Neuroscience $133 15 payments
  6. VRAYLAR Neuroscience $116 12 payments
  7. QELBREE $115 4 payments
  8. APLENZIN $112 7 payments
  9. ABILIFY MAINTENA $109 7 payments
  10. REXULTI Psychiatry $89 5 payments
  11. Other $1,018 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

175 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record